Phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience.
Semaglutide trials show sustained benefits across diverse populations and treatment settings, supporting its role in diabetes and weight management.
This PubMed-indexed study examined phase 3 clinical development of semaglutide (2015-2026): a comprehensive evidence-based review of trial designs, therapeutic outcomes and global clinical experience. Diabetes Res Clin Pract 2026 Nov 7:113648.
What the study was
- Study design
- Comprehensive evidence-based review of phase III trials
- Population
- Human participants or human evidence described in the PubMed abstract
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Diabetes research and clinical practice
Why it surfaced
Comprehensive evidence-based review of phase III trials with PubMed abstract evidence; scored conservatively for treatment innovation relevance and evidence maturity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.